Lucid Diagnostics (NASDAQ:LUCD) reported quarterly losses of $(0.19) per share which met the analyst consensus estimate. This is a 17.39 percent increase over losses of $(0.23) per share from the same period last year. The company reported quarterly sales of $1.20 million which missed the analyst consensus estimate of $1.42 million by 15.83 percent. This is a 15.10 percent increase over sales of $1.04 million the same period last year.